What Telix Pharmaceuticals does

Telix Pharmaceuticals Limited is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, and dual-listed on the ASX and NASDAQ under the ticker TLX. The company develops and commercializes theranostic radiopharmaceuticals — molecularly targeted diagnostic imaging agents paired with matched therapeutic radioligands — with a disease focus on urologic oncology (prostate, kidney), neuro-oncology (glioma, glioblastoma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The commercial core is the PSMA-PET imaging franchise, anchored by Illuccix (kit for preparation of gallium-68 gozetotide injection, approved by FDA, TGA, and Health Canada, plus 19 European markets via DCP) and its next-generation successor Gozellix, which launched in the U.S. in 2025 with permanent HCPCS code A9616 and CMS Transitional Pass-Through status.

Name

Telix Pharmaceuticals

Legal name

Telix Pharmaceuticals Limited

Website

http://www.telixpharma.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that develops and commercializes theranostic radiopharmaceuticals (diagnostic imaging agents and matched therapeutic radioligands), anchored by FDA- and EMA-approved PSMA-PET imaging agents Illuccix and Gozellix for prostate cancer, serving hospitals, nuclear medicine departments, and urology clinics worldwide.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Oncology Telemedicine Platforms (HLALAGAH), CAR-T & TCR-T Therapies (HLAAABAC), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)

Keywords

• Theranostic radiopharmaceuticals
• Diagnostic imaging agents
• Cancer radioligand therapy
• PSMA-PET imaging
• Radiopharmacy distribution

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Commercial product sales (Precision Medicine): Sales of FDA/TGA/Health Canada-approved PSMA-PET imaging agents Illuccix and Gozellix, plus newer launches of Zircaix and Pixclara (subject to approval), generating FY2025 Precision Medicine revenue of approximately $622 million with 22% YoY growth. Pricing is per unit dose (kit for preparation of gallium-68 gozetotide injection).
2. Third-party radiopharmacy distribution (RLS): Revenue from the RLS Radiopharmacies network acquired January 2025, providing third-party PET/SPECT product sales and distribution service fees. Q3 2025 RLS third-party revenue was $47M; Q2 2025 was $46M. RLS revenue excludes Illuccix/Gozellix product sales.
3. Strategic collaboration milestones and royalties: Telix is eligible to receive up to $2.1 billion in aggregate development and commercial milestone payments plus low double-digit royalties from its Regeneron collaboration (April 2026). Regeneron paid $40M upfront for access to four initial therapeutic programs with options to expand to eight programs under a 50/50 cost/profit share.
4. Future therapeutic product sales (pipeline): Anticipated revenue from therapeutic radioligand product launches (e.g., TLX591-Tx for mCRPC, TLX101-Tx for glioblastoma, TLX250-Tx for ccRCC, TLX597-Tx next-gen RLT). Management expects first therapeutic commercial launch in 2028.
5. Convertible bond financing: Telix raised US$600 million in 1.50% convertible notes due 2031 (upsized from $550M) in April 2026, with a 37.5% conversion premium. Proceeds used to repurchase A$637M of existing A$650M convertible bonds due 2029. An earlier A$600M convertible bond offering was completed in July 2024.

Go-to-market motion4 records

Core offering

Telix Pharmaceuticals develops and commercializes therapeutic and diagnostic ("theranostic") radiopharmaceuticals for oncology and rare diseases. Its commercial core is the FDA-approved PSMA-PET imaging franchise of Illuccix and Gozellix (gallium-68 gozetotide kits for prostate cancer imaging), supported by Telix Manufacturing Solutions (TMS) and a late-stage pipeline of radioligand therapies (e.g., TLX591-Tx, TLX101-Tx, TLX250-Tx), imaging agents (Pixclara, Zircaix), the SENSEI drop-in gamma probe, and QDOSE dosimetry software.

Product overview

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that operates a vertically integrated theranostic radiopharmaceutical platform spanning therapeutic and diagnostic ('theranostics') products. The portfolio architecture is a platform-plus-modules model: the lead commercial PSMA-PET imaging franchise includes Illuccix® (kit for the preparation of gallium-68 gozetotide injection) and its next-generation successor Gozellix®, both approved in the U.S. and key European markets, forming the Precision Medicine commercial core. These are supported by Telix Manufacturing Solutions (TMS) — a network of radiopharmacies (RLS), production facilities, and cyclotrons across the U.S. (Sacramento, North Melbourne-equivalent), Belgium (Brussels South/Seneffe), Japan (Yokohama), and Australia — together with the ARTMS QUANTM Irradiation System (QIS), IBA Cyclone KIUBE cyclotrons, and GE FASTlab production technology. The investigational imaging pipeline adds TLX101-Px (Pixclara®/Pixlumi®, 18F-FET for glioma), TLX250-Px (Zircaix®, 89Zr-girentuximab for kidney cancer), and the AlFluor™ radiochemistry platform. The therapeutic pipeline is anchored by TLX591-Tx (ProstACT Global Phase 3 lutetium-177 rosopatamab tetraxetan for mCRPC), TLX597-Tx (next-gen PSMA RLT in OPTIMAL-PSMA Phase 2), TLX101-Tx (131I-iodofalan for glioblastoma in IPAX-BrIGHT Phase 3), TLX250-Tx (177Lu-DOTA-girentuximab for ccRCC, LUTEON/STARLITE-1), TLX252 (225Ac-DOTA-girentuximab targeted alpha therapy), TLX090 (153Sm-DOTMP for bone pain, SOLACE Phase 1), TLX592 (225Ac-PSMA-RADmAb), and TLX400 (FAP-targeting therapy). Adjacent medical-technology and software modules include the SENSEI® drop-in gamma probe (for robotic-assisted radio-guided surgery) and QDOSE® dosimetry software (510(k)-cleared, CE-marked, MDR-certified). Regeneron partnership (April 2026) added a 50/50 cost- and profit-sharing program structure on up to eight solid-tumor radiopharmaceutical programs, and the United Imaging collaboration (June 2026) integrates Telix's imaging agents with United Imaging's scanners and AI. AI-enabled PSMA-PET work is conducted via the PROMISE-PET registry collaboration with University Hospital Essen.

Differentiator

Problem solved

Functional benefit

Brands

• Illuccix: First-generation PSMA-PET imaging agent (kit for the preparation of gallium-68 gozetotide injection) for detection and localization of PSMA-positive lesions in men with prostate cancer; approved by TGA, FDA, Health Canada, BASG (Austria), AEMPS (Spain), BfArM (Germany), AFMPS (Belgium), AIFA (Italy), and 19 European markets.
• Gozellix
• Zircaix
• Pixclara
• Pixlumi
• SENSEI
• QDOSE
• AlFluor
• Telix Manufacturing Solutions (TMS)
• ARTMS QUANTM Irradiation System (QIS)
• Scintimun

Products and services

• Illuccix® Telix's lead PSMA-PET imaging agent (kit for the preparation of gallium-68 gozetotide injection) for detection and localization of PSMA-positive lesions in adults with prostate cancer, approved by the FDA and TGA in the United States and Australia and rolled out across European markets.
• Gozellix® Next-generation PSMA-PET imaging agent (kit for the preparation of gallium-68 (68Ga) gozetotide injection) for prostate cancer, offering up to 6-hour shelf life, scalable production via gallium generators or cyclotron-based methods, and full CMS reimbursement with permanent HCPCS Level II code A9616 and TPT status.
• TLX101-Px (Pixclara®) Investigational PET imaging agent (Floretyrosine F 18 / 18F-FET) for the imaging and characterization of recurrent or progressive glioma in adult and pediatric patients, with Orphan Drug and Fast Track designations from the FDA; targets LAT1 and LAT2 membrane transport proteins. EU brand: Pixlumi®.
• TLX250-Px (Zircaix®) Kidney cancer imaging agent (89Zr-DFO-girentuximab, TLX250-CDx) PET/CT for characterization of renal malignancies including clear cell renal cell carcinoma (ccRCC). BLA under review with FDA.
• TLX591-Tx (177Lu-rosopatamab tetraxetan) PSMA-targeted lutetium-177 radio antibody-drug conjugate (rADC) therapy candidate for metastatic castration-resistant prostate cancer (mCRPC). ProstACT Global Phase 3 study Part 1 met primary safety/tolerability objectives; Part 2 expansion underway targeting approximately 490 patients.
• TLX597-Tx Next-generation PSMA-targeting radioligand therapy candidate for prostate cancer being developed to improve patient access to lutetium therapy. OPTIMAL-PSMA Phase 2 trial dosimetry data presented at IPCS 2026 showed low salivary gland and kidney uptake, supporting dose intensification. OPTIMAL-E Phase 2 in mHSPC initiating.
• TLX250-Tx (177Lu-DOTA-girentuximab) Investigational 177Lu-DOTA-girentuximab radioligand therapy for clear cell renal cell carcinoma (ccRCC). Pivotal LUTEON trial approved in Australia as monotherapy in advanced metastatic ccRCC. STARLITE-1 Phase 1b/2 trial investigating combination with cabozantinib and nivolumab.
• TLX090 (153Sm-DOTMP) Therapeutic radiopharmaceutical candidate (Samarium-153-DOTMP) for the palliation of bone pain in patients with osteoblastic metastatic disease. Phase 1 SOLACE trial first patient dosed October 2025. Acquired via QSAM Biosciences acquisition.
• TLX592 (225Ac-PSMA-RADmAb) Investigational targeted alpha therapy (Actinium-225 labeled PSMA radio antibody) for advanced metastatic castration-resistant prostate cancer. HREC application submitted in Australia for Phase 1 first-in-human therapeutic study.
• TLX400 (177Lu-DOTAGA.Glu.(FAPi)2) Fibroblast Activation Protein (FAP)-targeting radioligand therapy candidate in-licensed by Telix in March 2025. Demonstrated clinical antitumor activity and manageable safety in advanced sarcoma patients in Journal of Nuclear Medicine publication. Differentiated by novel structure for prolonged tumor retention.
• TLX252 (225Ac-DOTA-girentuximab) Actinium-225 labeled CAIX-targeting investigational therapy for renal cancer. Being investigated in syngeneic murine tumor models and combined with DNA damage response inhibitors and immune checkpoint inhibitors in CAIX-positive renal cancer.
• SENSEI® drop-in gamma probe Miniature drop-in gamma probe technology designed specifically for robotic-assisted surgery, registered with the Australian TGA, the U.S. FDA, and has CE Mark for use in the European Economic Area. Used with radiotracers to identify cancer deposits and occult lymph nodes. Acquired via Lightpoint Medical acquisition.
• QDOSE® dosimetry software Dosimetry software with 510(k) clearance from the FDA, CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). Used in nuclear medicine dosimetry workflows.
• AlFluor™ radiochemistry platform Novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF) launched by Telix Precision Medicine. Enables flexible radiolabeling of PSMA with either AlF or gallium-68 (68Ga). Includes strategic agreement with University Hospital Ghent and Ghent University for [18F]AlF-PSMA-11.
• Scintimun® Telix diagnostic imaging product referenced as part of the company's commercial and late-stage precision medicine products portfolio.

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability6 records

Feature10 records

Recent moves11 records

Expansion highlights7 records

Broad incumbents

• Novartis: Novartis is the dominant player in radioligand therapy with Pluvicto (lutetium-177 vipivotide tetraxetan) for mCRPC and Lutathera for neuroendocrine tumors. As a large-cap incumbent, Novartis competes directly with Telix's PSMA-targeted therapeutic pipeline (TLX591-Tx, TLX597-Tx) and has first-mover advantage in the commercial radioligand therapy market.
• GE HealthCare: GE HealthCare is a broad incumbent in molecular imaging, manufacturing PET scanners (including the GE FASTlab production platform used by Telix for Gozellix), radiopharmaceuticals, and contrast media. As a diversified imaging and diagnostics major, it overlaps with Telix across the imaging value chain.
• Siemens Healthineers: Siemens Healthineers is a broad incumbent in medical imaging and radiation oncology (via Varian), with a strategic clinical collaboration announced with Telix in December 2025. It overlaps with Telix across PET imaging hardware, radiopharmacy, and radiation therapy—adjacent rather than direct competition.
• Bayer: Bayer is a broad incumbent in radiopharmaceuticals with Xofigo (radium-223) for bone metastases in prostate cancer and an active radioligand therapy pipeline. Bayer competes with Telix in the prostate cancer theranostics space and is developing next-generation targeted radiopharmaceuticals.
• Bracco Imaging: Bracco Imaging is a broad incumbent in diagnostic imaging agents and contrast media with a growing radiopharmaceutical portfolio. It competes with Telix in the broader molecular imaging market and has infrastructure for nuclear medicine distribution.

Direct peers

• Curium: Curium is a global radiopharmaceutical manufacturer and distributor that competes directly with Telix in nuclear medicine imaging agents and operates a vertically integrated production and distribution model similar to Telix Manufacturing Solutions (TMS) and RLS Radiopharmacies.
• Lantheus Holdings: Lantheus is a direct competitor in PSMA-PET imaging with Pylarify (piflufolastat F-18) approved for prostate cancer. Both companies target the same indication with similar radiopharmaceutical imaging agents and compete for hospital and urology clinic accounts in the U.S. and Europe.
• ITM Isotope Technologies Munich: ITM is a direct peer in radioligand therapy with a pipeline of lutetium-177-based targeted radionuclide therapies for solid tumors. ITM also operates as a manufacturer of medical isotopes, competing with Telix on supply chain and pipeline assets in the radiopharmaceutical theranostics space.

Emerging players

• Telix Pharmaceuticals (acquired by AstraZeneca: Fusion Pharmaceuticals): Fusion Pharmaceuticals (acquired by AstraZeneca) is an emerging player in targeted alpha therapies using actinium-225, directly comparable to Telix's TLX252 and TLX592 alpha-emitting programs. Both companies pursued radiopharmaceutical conjugates for solid tumors before their respective strategic transactions.

Others

• Cardinal Health: Cardinal Health is a commercial radiopharmacy distribution partner (supplies finished unit doses of Gozellix to U.S. customers) and operates its own radiopharmaceutical distribution network. While primarily a logistics partner, it is an adjacent participant in the U.S. nuclear medicine supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/18067478
• Xx.com/TelixPharma
• Facebookfacebook.com/TelixPharma

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries8 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A12 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telix Pharmaceuticals